Of the patients with pre-transplant diabetes and those who developed de novo diabetes after transplantation (n = 44), 5 patients were taking sodium–glucose cotransporter 2 (SGLT2 inhibitors), and 4 patients were taking dipeptidyl peptidase-4 inhibitors at the end of the study. Here, SLC5A2 is linked to diabetes mellitus.